Beta Bionics, Inc. (BBNX) income statement
BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.33−0.39 (-2.65%)
Close on Nov 18, 2026Market cap $779.08MP/E –Yield –
Beta Bionics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 58.6%
- Operating margin
- -72.7%
- Net margin
- -65.3%
- Return on equity, FY2025
- -346.5%
Financial strength
- Current ratio
- 8.92
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 248.4%
Valuation
- P/E ratio
- –
- Price to sales
- 6.12
- Price to book
- 1.94
- Dividend yield
- –
See a number that looks wrong?